What is KPV?
KPV is a tripeptide consisting of three amino acids: lysine (K), proline (P), and valine (V). It represents the carboxy-terminal tripeptide of alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring neuropeptide with well-established anti-inflammatory properties.
Researchers identified KPV as the minimal active sequence of α-MSH needed to retain most of its immunomodulatory activity, while avoiding the melanotropic (pigmentation-stimulating) and other effects of the full-length peptide. This makes KPV a targeted research compound for inflammatory conditions.
How KPV Works
KPV exerts its effects through several immune pathways:
- Melanocortin receptor modulation: Binds to melanocortin receptors (MC1R, MC3R) expressed on immune cells and epithelial cells, dampening inflammatory signaling
- NF-κB inhibition: Blocks the NF-κB pathway, a master regulator of inflammatory gene expression
- Cytokine suppression: Reduces production of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6
- Epithelial barrier support: Appears to strengthen intestinal epithelial tight junctions, reducing gut permeability
- Macrophage polarization: May shift macrophage activity toward anti-inflammatory (M2) phenotype
Research Summary
Inflammatory Bowel Disease (IBD)
A 2008 study in Inflammatory Bowel Diseases demonstrated that KPV significantly reduced intestinal inflammation in murine colitis models, with effects comparable to higher doses of full-length α-MSH. KPV was effective when administered orally, intraperitoneally, or via enema formulations.
Epithelial Inflammation
Research published in the Journal of Clinical Investigation (2008) showed KPV inhibits inflammation in intestinal epithelial cells in response to bacteria, suggesting a role in mucosal immune regulation beyond simple cytokine suppression.
Sepsis Models
KPV has been investigated in systemic inflammatory models, with findings suggesting it reduces pathological immune activation during infection-driven inflammation.
Skin Applications
Given α-MSH’s known role in skin biology, KPV has been investigated for dermatological inflammatory conditions, with preliminary research suggesting anti-inflammatory effects in skin models.
Safety Considerations
- Very small tripeptide with limited immunogenicity potential
- No published toxicity data in humans
- Animal studies show no significant adverse effects at effective doses
- Oral bioavailability is being actively researched; nanoparticle delivery systems are being investigated to improve gut absorption
- Administered subcutaneously or orally in research settings
Medical Disclaimer: KPV is not approved by the FDA for human use. This information is for educational purposes only. Do not use peptides without consulting a licensed healthcare provider.
Legal & Regulatory Status
KPV is not FDA-approved for any therapeutic use and is not listed on the FDA’s approved bulk drug substance list for compounding. It is available commercially for legitimate laboratory research. Its legal status for human use varies by jurisdiction.
Related Reading
- MOTS-c and KPV: Longevity Peptides in Research — KPV alongside MOTS-c: inflammation, gut health, and longevity research context
- Anti-Aging Peptides: What the Research Actually Shows — Broader landscape of anti-inflammatory and longevity peptides
- Peptide Safety: What to Know Before Starting — Risk framework for early-stage research peptides
Safety Profile Summary
KPV demonstrates a favorable safety profile in preclinical studies with no significant toxicity observed. It is a very small tripeptide that appears well-tolerated in animal models. Human clinical data is not yet available. The peptide's short length may reduce immunogenicity risk.
References & Further Reading
- 1. Catania A, et al. Alpha-Melanocyte-Stimulating Hormone in the Modulation of Host Reactions. Endocr Rev. 1993;14(5):564-76. [PubMed ↗]
- 2. Kannengiesser K, et al. Melanocortin-Derived Tripeptide KPV Has Anti-Inflammatory Effects in Murine Models of Colitis. Inflamm Bowel Dis. 2008;14(3):324-31. [PubMed ↗]
- 3. Dalmasso G, et al. PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation. Gastroenterology. 2008;134(1):166-78. [PubMed ↗]
- 4. Brzoska T, et al. Alpha-Melanocyte-Stimulating Hormone and Related Tripeptides: Biochemistry, Antiinflammatory and Protective Effects in Vitro and in Vivo. Endocr Rev. 2008;29(5):581-602. [PubMed ↗]